Affymetrix PT Raised to $8.00 (AFFX)
Research analysts at Maxim Group increased their target price on shares of Affymetrix (NASDAQ:AFFX) from $6.00 to $8.00 in a report released on Monday, Analyst Ratings Network reports. The firm currently has a “buy” rating on the stock. Maxim Group’s target price suggests a potential upside of 30.29% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Goldman Sachs Group Inc. raised their price target on shares of Affymetrix (NASDAQ:AFFX) from $3.70 to $4.00 in a research note to investors on Friday. They now have a “sell” rating on the stock. Separately, analysts at Mizuho raised their price target on shares of Affymetrix (NASDAQ:AFFX) from $6.00 to $8.00 in a research note to investors on Monday, September 9th. They now have a “buy” rating on the stock. Finally, analysts at Thomson Reuters/Verus upgraded shares of Affymetrix (NASDAQ:AFFX) from a “hold” rating to a “buy” rating in a research note to investors on Monday, September 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. Affymetrix has a consensus rating of “Hold” and a consensus price target of $6.10.
Affymetrix (NASDAQ:AFFX) opened at 6.14 on Monday. Affymetrix has a 52 week low of $2.96 and a 52 week high of $6.51. The stock’s 50-day moving average is $5.68 and its 200-day moving average is $4.49. The company’s market cap is $439.4 million.
Affymetrix (NASDAQ:AFFX) last released its earnings data on Wednesday, July 31st. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.05. The company had revenue of $79.46 million for the quarter, compared to the consensus estimate of $78.53 million. During the same quarter in the previous year, the company posted ($0.02) earnings per share. The company’s revenue for the quarter was up 19.7% on a year-over-year basis. Analysts expect that Affymetrix will post $0.09 EPS for the current fiscal year.
Affymetrix, Inc (NASDAQ:AFFX) is engaged in the development, manufacture, sale and service of consumables and systems for genetic analysis in the life sciences and clinical healthcare markets.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.